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The physiological functions of the acute phase protein serum amyloid P (SAP) component are not well defined,
although they are likely to be important, as no natural state of SAP deficiency has been reported. We have investigated
the role of SAP for innate immunity to the important human pathogen Streptococcus pneumoniae. Using flow
cytometry assays, we show that SAP binds to S. pneumoniae, increases classical pathway–dependent deposition of
complement on the bacteria, and improves the efficiency of phagocytosis. As a consequence, in mouse models of
infection, mice genetically engineered to be SAP-deficient had an impaired early inflammatory response to S.
pneumoniae pneumonia and were unable to control bacterial replication, leading to the rapid development of fatal
infection. Complement deposition, phagocytosis, and control of S. pneumoniae pneumonia were all improved by
complementation with human SAP. These results demonstrate a novel and physiologically significant role for SAP for
complement-mediated immunity against an important bacterial pathogen, and provide further evidence for the
importance of the classical complement pathway for innate immunity.
Citation: Yuste J, Botto M, Bottoms SE, Brown JS (2007) Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog 3(9): e120. doi:10.
1371/journal.ppat.0030120
Introduction
The pentraxin serum amyloid P (SAP) is a glycoprotein that
is a major constituent of human serum, present in concen-
trations of about 30–50 lg/ml. Pentraxin proteins are
distinguished by their pentameric assembly and calcium-
dependent ligand binding, and include another important
serum protein, C reactive protein (CRP). Pentraxins are
components of the acute phase response, with serum levels of
SAP increasing markedly in mice during sepsis [1,2]. No
known natural state of SAP deﬁciency has been identiﬁed,
suggesting that SAP has a vital role in human health, but the
exact function(s) of SAP are ill-deﬁned. SAP binds to DNA,
chromatin, and apoptotic cells, and is thought to aid their
clearance [3,4]. However, by binding to amyloid ﬁbrils and
stabilising their structure, SAP also promotes amyloid
persistence and is therefore an important component of
the disease amyloidosis [5–7]. Interactions of SAP with the
immune system have also been described, the physiological
relevance of which is not clear. These include binding to the
complement factor C1q and preventing the inhibitory
function of the complement regulatory component C4
binding protein (C4BP), both of which can lead to activation
of the classical pathway of complement [8–11], and improving
Fcc receptor–mediated phagocytosis of zymosan and apop-
totic cells [12–15]. In addition, SAP can bind to structures
found on microbial surfaces, including lipopolysaccharide
(LPS), phosphorylcholine (PC), and terminal mannose or
galactose glycan residues [16–20]. As a consequence, SAP can
bind to a range of microbes, including Gram-positive and
Gram-negative bacterial pathogens and human inﬂuenza A
virus [21,22].
These data suggest that SAP might act as a pathogen
recognition receptor and assist innate immunity to microbial
pathogens, which is analogous to the known role of CRP, to
which SAP has 51% homology at the amino acid level [19,23].
Several studies have investigated the potential role of SAP for
host immunity, but have produced conﬂicting results. SAP
enhances killing of Listeria monocytogenes by macrophages
without affecting phagocytosis [24], inhibits the growth of
intra-erythrocyte malaria parasites [25], reduces uptake of
Mycobacterium tuberculosis by macrophages [26,27], and pre-
vents inﬂuenza A infection of cell cultures [22], phenotypes
which could improve immunity to these pathogens. However,
data from experimental infections in SAP-deﬁcient mice have
shown that SAP has little effect on immunity to inﬂuenza A
[28]. Furthermore, SAP prevents classical pathway comple-
ment deposition and phagocytosis of rough strains of
Escherichia coli, and SAP-deﬁcient mice are protected against
infection with rough strains of E. coli and Streptococcus pyogenes
[29,30]. In contrast, SAP does not bind to or affect
phagocytosis of a smooth strain of E. coli, and SAP-deﬁcient
mice had increased susceptibility to this E. coli strain by
unknown mechanisms [29,30]. At present, whether SAP aids
immunity to a common human pathogen has not been clearly
demonstrated.
One human pathogen of major importance worldwide is
Streptococcus pneumoniae. S. pneumoniae is the second most
common cause of death due to bacterial infection, is
responsible for the majority of cases of pneumonia, and is a
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infants and adults [31–33]. The high mortality of severe S.
pneumoniae infections (over 20% even if treated with
appropriate antibiotics) and the spread of antibiotic resist-
ance amongst clinical strains underline the importance of
understanding host immunity to S. pneumoniae. Experimental
and human data have convincingly demonstrated the
essential role of the complement system for preventing S.
pneumoniae infections and for controlling replication of S.
pneumoniae within the lungs and the systemic circulation [34–
36]. We have previously reported that, in contrast to S.
pyogenes, even in the absence of speciﬁc acquired antibody the
classical pathway is the most important complement pathway
for innate immunity to S. pneumoniae [34]. The mechanisms by
which the classical pathway is activated by S. pneumoniae
infection include recognition of PC on the bacterial surface
by natural IgM and CRP [34,37–40], and binding of bacterial
capsular polysaccharide to the lectin SIGN-R1 expressed on
marginal zone macrophages within the spleen [41]. As SAP
also binds to PC and is known to interact with the classical
pathway, we hypothesised that SAP could be an additional
mediator of classical pathway activity against S. pneumoniae
and contribute towards innate immunity to this important
pathogen. In this study, we investigated the role of SAP for
immunity to S. pneumoniae, in particular its role during
complement activation, phagocytosis, and infection in mouse
models of disease using mice genetically engineered to be
deﬁcient in SAP.
Results
SAP Binds to Different Capsular Serotypes of S.
pneumoniae
Whole-cell ELISAs were used to investigate whether human
SAP (hSAP) binds to three S. pneumoniae strains representing
capsular serotypes (STs) 2, 23F, and 4 using the smooth E. coli
O111:B4 strain, which is known not to bind to SAP [30], as a
negative control. Dose-dependent binding to puriﬁed hSAP
was demonstrated to all three S. pneumoniae strains (Figure
1A). To conﬁrm these results for live bacteria in a
physiological medium, hSAP binding to S. pneumoniae in-
cubated in human serum was assessed by a ﬂow cytometry
assay using the S. pyogenes H372 strain and the E. coli O111:B4
as positive and negative controls, respectively. For all three S.
pneumoniae strains and S. pyogenes, a signiﬁcant proportion of
bacteria were positive for hSAP (ST2 38% standard deviation
[SD] 10, ST4 32% SD 8.3, ST23F 39% SD 12, H372 50% SD
2.2), whereas the E. coli O111:B4 strain showed no signiﬁcant
binding to hSAP (6.7% SD 4.0) (Figure 1B). Addition of EDTA
reduced the proportion of the ST2 S. pneumoniae strain
positive for SAP (Figure 1C), demonstrating that SAP binding
was calcium dependent. Furthermore, the presence of PC
inhibited binding of both SAP and CRP (used as a positive
control, as CRP is known to bind to S. pneumoniae cell wall PC)
to a similar degree, suggesting that PC is a major ligand for
SAP binding to S. pneumoniae (Figure 1D and 1E). Signiﬁcant
levels of SAP binding still occurred in the presence of PC or
high concentrations of EDTA, and this might reﬂect some
non-speciﬁc binding of SAP to S. pneumoniae. These data show
that SAP can bind to a range of S. pneumoniae strains, and
therefore could potentially act as a pathogen recognition
receptor and mediate innate immune responses to this
pathogen.
C3b Deposition on S. pneumoniae Is Partially Dependent
on SAP
To determine whether SAP affects complement activation
by S. pneumoniae, C3b deposition on S. pneumoniae incubated in
serum from wild-type or mice genetically engineered to be
deﬁcient in SAP (Apcs
 /  mice) was analysed using a ﬂow
cytometry assay. Starting 1 min after incubation in serum,
C3b deposition on the ST2 S. pneumoniae strain was strongly
impaired in serum from Apcs
 /  mice at all time points
compared to the results for serum from wild-type mice
(Figure 2A and 2D). The proportion of bacteria positive for
C3b after incubation in serum from Apcs
 /  mice was also
reduced for the ST4 and ST23F strains (Figure 2B, 2C, and
2E). The effect of SAP deﬁciency on C3b deposition varied
between the three S. pneumoniae strains investigated, with a
very marked effect for the ST23F strain, a relatively weak
effect for the ST4 strain, and an intermediate effect on the
ST2 strain. Backcrossing of SAP-deﬁcient Apcs
 /  animals
onto the C57BL/6 genetic background results in the trans-
location of surrounding chromosomal DNA from the mouse
129 strain into the C57BL/6 strain, and this combination has
been shown to explain some of the phenotypes associated
with Apcs
 /  mice [12]. However, C3b deposition on the ST2
strain in serum from congenic C57BL/6 mice engineered to
carry a similar 129 fragment but no deletion of the SAP gene
(C57BL/6.129(D1Mit105–223)) [42] was identical to C3b
deposition in serum from wild-type C57BL/6 mice (unpub-
lished data), demonstrating that this genetic combination was
not responsible for the impaired C3b deposition detected in
serum from Apcs
 /  mice. Furthermore, C3 deposition on the
ST2 strain in Apcs
 /  serum was partially restored by addition
of serum from wild-type mice and by the addition of
exogenous hSAP (Figure 2F and 2G). These results conﬁrm
that the reduced complement deposition on S. pneumoniae in
serum from Apcs
 / mice is due to loss of SAP, and suggest that
hSAP has a similar functional effect on complement
activation by S. pneumoniae as mouse SAP.
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Author Summary
Serum amyloid P (SAP) is a protein that is found in high
concentrations in the blood, the exact function(s) of which are not
clear. However, no known natural state of SAP deficiency has been
identified, which suggests that SAP does have a vital role in human
health. SAP can bind to molecular patterns found on the surface of
bacteria, and it has been proposed that this may mark bacteria for
attack by the immune system. We have investigated whether SAP
helps protect against an important bacterial pathogen, Streptococ-
cus pneumoniae. We show that SAP binds to different strains of S.
pneumoniae, and that this leads to activation of an important
component of the immune response called the complement system.
Complement is particularly important for defence against S.
pneumoniae infections, and using animal models of infection, we
demonstrate that loss of SAP makes mice more susceptible to S.
pneumoniae pneumonia. These results suggest that SAP helps the
immune system to recognise invasion by bacteria and describe a
new mechanism required for control of S. pneumoniae infections.
This study may help the design of new therapeutic strategies to
prevent or treat important bacterial diseases.SAP Increases C3b Deposition on S. pneumoniae through
the Classical Pathway
As SAP has been shown to bind to C1q [9], the ﬁrst
component of the classical pathway, one mechanism by which
the SAP may aid C3b deposition on S. pneumoniae could
involve increasing C1q binding to the bacteria and thereby
activating the classical pathway. To investigate this possibility,
the three serotypes of S. pneumoniae were incubated with
physiological concentrations of puriﬁed human C1q protein
and hSAP protein, and the deposition of C1q on the bacteria
Figure 1. Binding of hSAP to ST2, ST4, and ST23F Strains of S. pneumoniae
(A) Results of whole-cell ELISAs presented as maximum ODs after incubation with different concentrations of hSAP (given below each column as lg/ml),
using the E. coli O111:B4 strain as a negative control. Error bars represent SDs, and asterisks mark significant p-values for comparisons of results for S.
pneumoniae in 20 lg/ml hSAP versus medium alone (2-tailed t tests, *p , 0.01, ***p , 0.0001).
(B) Examples of flow cytometry histograms demonstrating hSAP binding to the surface of the three different S. pneumoniae strains, the E. coli O111:B4
strain, and the S. pyogenes H372 strain (positive control) after incubation in human serum.
(C) Effect of different concentrations of EDTA on SAP binding to the ST2 S. pneumoniae strain in human serum. Error bars represent SDs, and asterisks
mark significant p-values for comparisons of results for EDTA versus serum alone (2-tailed t tests, ***p , 0.0001).
(D) Effect of addition of 100 mM PC on SAP and CRP binding to the ST2 S. pneumoniae strain in human serum. Grey columns, results for human serum;
white columns, results for human serum in the presence of PC. Addition of 100 mM bovine serum albumin had no effect on SAP binding (unpublished
data). Error bars represent SDs, and p-values are indicated above the columns.
(E) Examples of flow cytometry histograms demonstrating inhibition of hSAP binding to the surface of the ST2 S. pneumoniae strains by addition of 100
mM PC to human serum.
doi:10.1371/journal.ppat.0030120.g001
PLoS Pathogens | www.plospathogens.org September 2007 | Volume 3 | Issue 9 | e120 1210
SAP and Susceptibility to S. pneumoniaeanalysed using a ﬂow cytometry assay. For all three strains,
the presence of hSAP increased the deposition of hC1q on
the S. pneumoniae surface (Figure 3A–3D). Furthermore,
addition of exogenous hSAP to human sera increased C1q
deposition on all three S. pneumoniae serotypes (Figure 3E and
3F). To conﬁrm that the effects of SAP on C3b deposition are
mainly mediated by increased C1q deposition activating the
classical pathway, C3b deposition assays were repeated using
serum from mice with deﬁciencies of both SAP and C1q
(Apcs
 / .C1qa
 / ) with and without addition of exogenous
hSAP. In contrast to the results for Apcs
 /  serum, addition of
hSAP to Apcs
 / .C1qa
 /  serum had no effect on C3b
deposition on the ST2 S. pneumoniae strain (Figure 2H). These
data suggest that SAP-mediated C3b deposition on S.
pneumoniae is C1q and therefore classical pathway dependent.
Impaired Phagocytosis of S. pneumoniae in Serum from
Apcs
 /  Mice
To study the functional consequences of reduced comple-
ment deposition on S. pneumoniae in Apcs
 /  serum, we
Figure 2. Effects of SAP on C3b Deposition on S. pneumoniae Measured Using Flow Cytometry
(A) Time course of the proportion of ST2 S. pneumoniae bacteria positive for C3b after incubation in serum from wild-type and Apcs
 /  mice. For the
comparison of results for wild-type versus Apcs
 /  mice, p , 0.001 at all time points from 1 to 20 min.
(B and C) Proportion of ST4 (B) and ST23F (C) S. pneumoniae bacteria positive for C3b after incubation for 20 min in serum from wild-type and Apcs
 / 
mice.
(D and E) Examples of flow cytometry histograms of C3b deposition on ST2 (D) and ST23F (E) S. pneumoniae strains after incubation in PBS or serum
from wild-type or Apcs
 /  mice.
(F) Effect on the proportion of ST2 S. pneumoniae positive for C3b of addition of 10 lg/ml hSAP to serum from Apcs
 /  mice.
(G) Effect on the proportion of ST2 S. pneumoniae positive for C3b of addition of an equal volume of serum from wild-type mice to serum from Apcs
 / 
mice.
(H) Effect of addition of hSAP (50 lg/ml, white column) on C3b deposition on the ST2 S. pneumoniae strain in serum from Apcs
 / .C1qa
 /  mice. Grey
columns, results for Apcs
 / .C1qa
 /  serum; white columns, results for Apcs
 / .C1qa
 /  serum in the presence of hSAP.
For panels (A–C) and (F–H), error bars represent SDs, and in (A) when not visible are too small to be seen outside of the symbol. p-Values are calculated
using 2-tailed t tests.
doi:10.1371/journal.ppat.0030120.g002
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SAP and Susceptibility to S. pneumoniaeanalysed phagocytosis of S. pneumoniae in serum from Apcs
 / 
mice using ﬂow cytometry to assess the proportion of
ﬂuorescent bacteria associated with HL60 cells, a human
neutrophil cell line. In this assay, the association of
ﬂuorescent bacteria with phagocytes is mainly due to
phagocytosis of the bacteria rather than simple binding to
the cell surface [43]. Phagocytosis of all three S. pneumoniae
strains was mainly serum dependent, with only low levels of
uptake after incubation in Hank’s Balanced Salt Solution
(HBSS) medium alone (Figure 4). Phagocytosis was consis-
tently reduced when the bacteria were incubated with serum
from Apcs
 / mice compared to serum from wild-type mice for
the three S. pneumoniae strains investigated (Figure 4). The
level of phagocytosis was partially restored in serum from
Apcs
 /  mice when mixed with serum from wild-type mice or
by addition of exogenous hSAP (Figure 4A and 4E). However,
addition of hSAP to HBSS alone or to Apcs
 / .C1qa
 /  serum
did not stimulate phagocytosis of S. pneumoniae, suggesting
that the effects of hSAP are dependent on the classical
pathway (Figure 4E and 4F). These results are consistent with
the results of the C3b deposition assays, and indicate that
reduced opsonisation of S. pneumoniae with C3b in Apcs
 / 
serum is associated with a reduced efﬁciency of phagocytosis.
Clearance of S. pneumoniae from the Blood Is Impaired in
SAP-Deficient Mice
Clearance of S. pneumoniae from the circulation is thought
to be dependent on complement and on phagocytosis by the
reticuloendothelial system [44]. To test whether the effects of
SAP deﬁciency on complement deposition and phagocytosis
of S. pneumoniae result in an impaired ability to clear bacteria
from the blood, wild-type and Apcs
 / mice were inoculated by
i.v. injection with 2 3 10
5 cfu of the ST2 strain D39, and
bacterial cfu in the blood calculated by serial dilutions at 2
and 4 h post-inoculation and in spleen homogenates 4 h post-
inoculation (Figure 5). Apcs
 /  mice had between 2 and 3 logs
Figure 3. Effects of SAP on C1q Binding to S. pneumoniae Measured Using Flow Cytometry
(A–C) Proportion of ST2 (A), ST4 (B), and ST23F (C) S. pneumoniae bacteria positive for C1q after incubation in 90 lg/ml human C1q with or without
addition of 10 or 50 lg/ml hSAP.
(D) Example of flow cytometry histograms of C1q binding to ST4 S. pneumoniae after incubation in 90 lg/ml human C1q with or without addition of 50
lg/ml hSAP.
(E) Proportion of S. pneumoniae positive for C1q after incubation in human serum with (black shading) or without (grey shading) addition of 50 lg/ml
hSAP, using C1q-depleted serum (white shading) as a negative control.
(F) Example of flow cytometry histograms of C1q binding to ST2 S. pneumoniae after incubation in human serum with or without addition of 50 lg/ml
hSAP.
For panels (A–C) and (E), error bars represent SDs, and p-values are calculated using 2-tailed t tests.
doi:10.1371/journal.ppat.0030120.g003
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SAP and Susceptibility to S. pneumoniaegreater cfu in both the blood and spleen compared to wild-
type mice, demonstrating that Apcs
 /  mice have a marked
impairment in their ability to clear S. pneumoniae from the
systemic circulation consistent with the impaired phagocy-
tosis of S. pneumoniae found in SAP-deﬁcient serum.
SAP-Deficient Mice Are Susceptible to S. pneumoniae
Pneumonia
A mouse model of pneumonia was used to conﬁrm a
biological role of SAP for innate immunity to S. pneumoniae.
C57BL/6 mice are partially susceptible to the ST2 S. pneumo-
niae strain D39 after intranasal (i.n.) inoculation and there-
fore provide a sensitive model for identifying immunological
defects that result in increased susceptibility [34]. Groups of
wild-type and Apcs
 /  C57BL/6 mice were inoculated i.n. (to
mimic the natural route of infection) with 1310
6 cfu of D39
of S. pneumoniae and the development of lethal infection
monitored. Lethal disease developed faster in Apcs
 /  mice,
with a median time to fatal infection of 64 h (interquartile
range [IQR] 52 to 68 h) compared to 86 h for wild-type mice
(IQR 77 to 92 h), and all the Apcs
 /  mice developed lethal
infection whilst 33% of wild-type mice survived (Figure 6A).
Figure 4. Effect of SAP on Phagocytosis of S. pneumoniae
(A–C) Phagocytosis (presented as proportion of HL60 cells associated with fluorescent bacteria) of (A) ST2, (B) ST4, and (C) ST23F after incubation in
different dilutions of serum from wild-type (circles) or Apcs
 /  (squares) mice. Results for incubation in HBSS are shown by the triangle symbol, and for
the ST2 strain the results for a 50:50 mix of serum from wild-type and Apcs
 /  mice (diamonds) are also included.
(D) Example of a flow cytometry histogram of phagocytosis of ST2 S. pneumoniae by HL60 cells after incubation in HBSS or serum from wild-type or
Apcs
 /  mice.
(E) Effect of addition of 5 or 50 lg/ml exogenous hSAP on phagocytosis of the ST2 S. pneumoniae strain in serum from Apcs
 /  mice.
(F) Effect of addition of hSAP (50 lg/ml) on phagocytosis of the ST2 S. pneumoniae strain in serum from Apcs
 / .C1qa
 /  mice. Grey column, results for
Apcs
 / .C1qa
 / serum; white column, results for Apcs
 / .C1qa
 / serum in the presence of hSAP. For panels (A–C), (E), and (F), asterisks mark significant
p-values for comparisons of results for wild-type or mixed serum to Apcs
 / serum (2-tailed t tests, *p , 0.01, **p , 0.001, ***p , 0.0001). All error bars
represent SDs and when not visible are too small to be seen outside the symbol.
doi:10.1371/journal.ppat.0030120.g004
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SAP and Susceptibility to S. pneumoniaePlating of aliquots of blood obtained from the tail veins of
mice 48 h after i.n. inoculation demonstrated that all the
Apcs
 /  mice had large numbers of bacteria in the blood,
whereas only 44% of wild-type mice had detectable septicae-
mia (Figure 6B). Hence, Apcs
 /  mice are more susceptible to
S. pneumoniae pneumonia, and this increased susceptibility is
associated with increased levels of bacteria infection in the
blood.
SAP Aids Control of S. pneumoniae Replication in the Lung
and Blood
To characterise the role of SAP during innate immunity in
more detail, groups of wild-type and Apcs
 /  mice were culled
4 and 24 h after i.n. inoculation with 1 3 10
6 cfu of D39 and
the number of bacteria present in target organs calculated by
plating serial dilutions of bronchoalveolar ﬂuid (BALF), lung
and spleen homogenates, and the blood. After 4 h of
infection, there were slightly higher levels of S. pneumoniae
cfu in BALF and lung from Apcs
 /  mice compared to wild-
type mice (Table 1). By 24 h after inoculation, Apcs
 /  mice
had over 1 log greater bacterial cfu in the BALF, 2 logs in lung
homogenates, and 4 logs in the blood compared to wild-type
mice (Table 1), demonstrating that Apcs
 /  mice were unable
to control bacterial replication within the lung and systemic
circulation. To ensure that chromosomal translocation of 129
DNA surrounding the SAP gene into the C57BL/6 mouse
background was not responsible for the increased suscepti-
bility of the Apcs
 /  mice to S. pneumoniae infection, experi-
ments were repeated using the C57BL/6.129(D1Mit105–223)
congenic mice and C57BL/6 animals. No differences in
bacterial cfu were identiﬁed between these strains 24 h after
inoculation of ST2 S. pneumoniae, indicating that SAP
deﬁciency is likely to be responsible for the phenotype seen
in Apcs
 /  mice (unpublished data). To further link the
observed increased susceptibility of Apcs
 /  mice to S.
pneumoniae pneumonia to deﬁciency in SAP, Apcs
 /  mice
were supplemented by tail vein injection with 5 mg/kg of
hSAP 1 h prior to inoculation with D39, and the bacterial cfu
in target organs obtained at 24 h. Although there was wide
variation in the numbers of bacteria recovered between mice,
for all target organs the median S. pneumoniae cfu recovered
from Apcs
 /  mice complemented with hSAP were similar to
those for wild-type mice and 1 to 4 log fewer than the median
cfu recovered from Apcs
 /  mice given PBS alone (Table 1).
Inflammatory Responses to S. pneumoniae Pneumonia in
Apcs
 /  Mice
As well as opsonising bacteria, activation of the comple-
ment system stimulates pro-inﬂammatory responses to
Figure 5. Clearance of the ST2 S. pneumoniae Strain from Wild-Type and Apcs
 /  Mice Inoculated Intravenously with 1.0 3 10
6 cfu
Each data point represents log10 cfu/ml results for a single mouse, with the bar showing the median for each group.
(A) Results for blood 2 h after inoculation.
(B) Results for blood 4 h after inoculation.
(C) Results for spleen homogenates 4 h after inoculation. Data is obtained from one experiment that is representative of two separate experiments.
p-Values for Mann–Whitney U comparisons between wild-type and Apcs
 /  mice are given below the title for each panel.
doi:10.1371/journal.ppat.0030120.g005
Figure 6. Susceptibility of Apcs
 /  Mice to S. pneumoniae Pneumonia
(A) Progression to lethal disease in groups of nine wild-type (circles) and
Apcs
 /  (squares) mice inoculated i.n. with 1.0 3 10
6 cfu of ST2 S.
pneumoniae. For the comparison between wild-type and Apcs
 /  mice, p
¼ 0.004 (log rank test).
(B) S. pneumoniae cfu in blood recovered from wild-type (circles) and
Apcs
 /  (squares) mice 48 h after i.n. with 1.0 3 10
6 cfu of ST2 S.
pneumoniae. Bars represent the median cfu recovered for each group,
and the p-value for the comparison between wild-type and Apcs
 /  mice
was 0.041 (Mann–Whitney U test).
doi:10.1371/journal.ppat.0030120.g006
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SAP and Susceptibility to S. pneumoniaeinfection. To investigate the effect of SAP deﬁciency on the
inﬂammatory response to S. pneumoniae pneumonia, the levels
of pro-inﬂammatory cytokines were measured in BALF from
wild-type and Apcs
 /  mice 4 h and 24 h after i.n. inoculation
with 1 3 10
6 cfu of the S. pneumoniae D39 strain. At 4 h after
inoculation, despite the slightly higher numbers of bacterial
cfu in BALF and lungs of Apcs
 /  mice (Table 1), the levels of
TNF-a and IL-6 were lower in Apcs
 /  mice than in wild-type
mice (Figure 7A), suggesting that at this early stage of
infection Apcs
 /  mice had an impaired inﬂammatory cyto-
kine response to S. pneumoniae pneumonia. Levels of IL-12, IL-
10, MCP-1, or IFN-c in BALF at 4 h were very low or
undetectable (unpublished data). By 24 h, at which time point
Apcs
 /  mice had considerably greater numbers of S. pneumo-
niae within target organs (Table 1), the levels of IL-6, IL-12,
TNF-a, and MCP-1 in BALF were raised in Apcs
 /  mice
compared to those of wild-type mice (Figure 7B). The levels of
IL-10 and IFN-c in BALF at 24 h remained very low
(unpublished data). The consequences of differences in
inﬂammatory cytokines between Apcs
 /  and wild-type mice
were assessed by scoring the level of inﬂammation in lung
sections. There were no signiﬁcant differences in the score
for the degree of histological inﬂammation of the lungs 4 h
after inoculation (a median score of 15 for both Apcs
 /  and
wild-type mice), and although there was an increase in the
inﬂammation score 24 h after infection in the lungs from
Apcs
 / mice, with a median score of 70 (IQR 60–80) compared
to a median score of 30 (IQR 19–68) for wild-type mice, this
did not reach statistical signiﬁcance (p ¼ 0.48). Overall, these
results suggest that during the early stages of S. pneumoniae
pneumonia, there is a more pronounced pro-inﬂammatory
response in wild-type mice compared to Apcs
 /  mice.
However, at later stages of infection, when there is consid-
erably greater bacterial cfu in the target organs of Apcs
 / 
mice (Table 1), Apcs
 /  mice have more pronounced levels of
inﬂammation than wild-type mice.
Discussion
The pentraxin SAP is an abundant plasma protein in both
humans and mice, but its physiological role is not fully
understood. By analogy to the related proteins CRP, which is
known to mediate complement-dependent immunity
[38,39,45], and Pentraxin3 [46], a role for SAP in innate
immunity has been suggested. This possibility is supported by
data demonstrating that SAP can bind to pathogen-associated
structures such as PC and LPS [16,17,20]. Furthermore, SAP
may interact with the classical pathway component C1q
through its collagen binding site, and possibly stimulates
phagocytosis through Fcc receptors [9,10,13,14]. However, the
physiological relevance of these observations is unclear, and
although in vitro phenotypes associated with hSAP suggest it
may protect against a variety of pathogens, including tuber-
culosis, malaria, or inﬂuenza A [22,25–27], other authors have
shown that in mice SAP actually aids the virulence of S.
pyogenes and E. coli, possibly by preventing classical pathway–
mediated complement activity and phagocytosis [29,30].
Using SAP-deﬁcient mice, we have investigated the bio-
logical role of SAP during infection by the Gram-positive
pathogen S. pneumoniae. We have previously shown that the
classical pathway is vital for innate immunity to S. pneumoniae,
partially through recognition of S. pneumoniae by natural IgM
[34]. However, natural IgM-deﬁcient mice were markedly less
susceptible to S. pneumoniae infection than C1q-deﬁcient mice
[34], suggesting there are other mediators of classical pathway
activity against S. pneumoniae. The lectin SIGN-R1 has recently
been shown to be one such mediator, with binding of the S.
pneumoniae capsule to SIGN-R1 resulting in activation of the
classical pathway [41]. However, although SIGN-R1-deﬁcient
mice have an increased susceptibility to S. pneumoniae
infection, like natural IgM mice they are more resistant than
C1q-deﬁcient mice [41], indicating that additional molecules
may contribute to complement activation. CRP is also
thought to bind to S. pneumoniae and activate the classical
pathway [40,47], but is present only in low levels in mice and
therefore probably does not contribute strongly to innate
immunity in the mouse models of S. pneumoniae infection. As
SAP from different mammalian species can bind both to PC
and C1q [9,10,16,17], we hypothesised that SAP could also
contribute to the activation of the classical pathway by S.
pneumoniae, and therefore aid both innate and acquired
immunity to this important pathogen. This hypothesis is
supported by our data showing binding of hSAP to three
different capsular serotypes of S. pneumoniae, and impaired
C3b deposition on these S. pneumoniae strains in Apcs
 /  serum
compared to serum from wild-type mice. Furthermore, we
have shown that the binding of human C1q to S. pneumoniae is
increased by the presence of hSAP and that the effects of SAP
Table 1. Median cfu/ml Recovered from Target Organs of Wild-Type and Apcs
 / Mice (with and without Supplementation with 5 mg/
kg hSAP Intravenously) after i.n. Inoculation of 1 3 10
6 cfu of S. pneumoniae ST2 Strain D39
Organ 4 h (n ¼ 11) 24 h (n ¼ 6)
Wild-Type Apcs
 /  Wild-Type Apcs
 /  Apcs
 /  þ hSAP
BALF 6.00 6.42 3.19 4.69 3.58
(IQR) (5.94–6.19) (6.39–6.53) (3.07–4.32) (3.78–5.19) (3.31–4.59)
Lung 3.95 4.56 4.28 6.39 4.23
(IQR) (3.87–4.10) (4.28–4.77) (3.97–4.92) (6.32–6.56) (3.47–5.96)
Blood 0 0 2.06 6.31 3.18
(IQR) (0–5.10) (6.02–6.80) (0–7.02)
Spleen 0 0 2.12 5.65 1.47
(IQR) (0–4.41) (5.12–5.83) (0–5.23)
doi:10.1371/journal.ppat.0030120.t001
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SAP and Susceptibility to S. pneumoniaeon complement are dependent on an intact classical pathway.
The reduced complement activity in SAP-deﬁcient serum
versus S. pneumoniae results in an impaired ability of SAP-
deﬁcient mice to control S. pneumoniae replication within both
the lungs and the bloodstream, leading to uncontrolled
infection in a mouse model of pneumonia. This phenotype is
very similar to that seen in mice deﬁcient in natural IgM [34],
and the data support the hypothesis that SAP and natural IgM
both contribute, along with SIGN-R1 and CRP, towards
classical pathway–mediated immunity to S. pneumoniae.
Previous reports that SAP does not aid immunity to S.
pneumoniae after intravenous (i.v.) inoculation [48] used wild-
type mice infected with bacteria that had been incubated with
SAP rather than SAP-deﬁcient animals, and this model was
therefore probably too insensitive to identify the effects we
have shown for SAP.
Reduced complement activity results in increased suscept-
ibility to infection by impairing C3b-mediated clearance of
bacteria by phagocytes and/or by decreasing complement-
mediated inﬂammatory responses to infection [44,49,50]. Our
results suggest that both mechanisms could affect the
susceptibility of Apcs
 /  mice to S. pneumoniae. Uptake of the
three different S. pneumoniae strains by a neutrophil-like cell
line was impaired in Apcs
 /  serum, and clearance of S.
pneumoniae from the systemic circulation after i.v. inoculation,
which is mainly dependent on phagocytosis by the retic-
uloendothelial system [51], was markedly reduced in Apcs
 / 
mice. These data suggest that by reducing opsonisation of S.
pneumoniae with C3b, SAP deﬁciency results in impaired
phagocytosis. The effects of SAP on phagocytosis of S.
pneumoniae were serum- and classical pathway–dependent,
with no stimulation of phagocytosis when SAP was added to
medium alone or serum deﬁcient in C1q, indicating that SAP
assisted phagocytosis through classical pathway activity and
not by direct binding to Fcc receptors. In addition, we found
that in BALF from Apcs
 /  mice obtained at an early stage of
infection there were lower levels of the pro-inﬂammatory
cytokines TNF-a and IL-6 despite containing slightly greater
numbers of cfu than wild-type mice in BALF and lung
homogenates at this stage. Hence, the early pro-inﬂammatory
response to S. pneumoniae pneumonia was impaired in Apcs
 / 
mice, and this may contribute to the increased susceptibility
of these mice. Whether the reduced inﬂammatory responses
in Apcs
 /  mice are due to loss of direct effects of SAP on
modulating the inﬂammatory response, or is secondary to
reduced complement activation and phagocytosis, requires
further evaluation. The increased inﬂammation in Apcs
 / 
mice compared to wild-type mice at 24 h probably reﬂects the
overwhelming infection present in Apcs
 /  mice at this stage
rather than direct effects of SAP deﬁciency.
Figure 7. Cytokine Levels in BALF Recovered from Wild-Type or Apcs
 /  Mice 4 h or 24 h after i.n. Inoculation with 1.0310
6 cfu of ST2 S. pneumoniae
Error bars represent SDs, and the p-values (2-tailed t tests) for comparison between wild-type and Apcs
 / mice are given below the title for each panel.
(A) Cytokine levels 4 h after inoculation.
(B) Cytokine levels 24 h after inoculation.
doi:10.1371/journal.ppat.0030120.g007
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SAP and Susceptibility to S. pneumoniaeAlthough human and murine SAP have a high degree of
homology at the amino acid level and both bind to PC, they
do have some differences in their structure and interactions
with other proteins [19]. Furthermore, CRP is the major
component of the acute phase response in humans and SAP,
although present in high concentrations in human sera, is the
major acute phase response protein in mice [2]. Hence, to
identify the possible human relevance of results obtained
with Apcs
 /  mice, we have complemented our assays using
hSAP. Complementation of Apcs
 /  serum with hSAP restored
C3b deposition on bacteria and phagocytosis close to the
levels seen with wild-type serum, and administration of hSAP
before infection with S. pneumoniae increased the resistance of
Apcs
 /  mice to infection. Furthermore, the evidence for SAP-
dependent C1q deposition on S. pneumoniae was obtained with
human reagents. These data suggest that SAP is also
important for classical pathway–mediated host immunity to
S. pneumoniae in humans as well as mice. As S. pneumoniae is one
of the commonest causes of infant mortality in the develop-
ing world [32], a role for SAP in preventing serious S.
pneumoniae infections helps explain why there is no natural
state of SAP deﬁciency.
In contrast to our results with S. pneumoniae pneumonia,
Apcs
 /  mice are protected against infection with S. pyogenes
inoculated intraperitoneally despite a high level of SAP
binding to the bacteria [30]. A possible explanation for the
differences in the effect of SAP on immunity between these
related pathogens could be differences in their interaction
with the complement system. We have previously shown that
the classical pathway is the dominant pathway for innate
immunity to S. pneumoniae [34], whereas the alternative
pathway is more important for innate immunity to S. pyogenes
[52]. As the classical pathway does not contribute strongly
towards complement activation by most strains of S. pyogenes
[52], SAP may not be able to aid innate immunity to this
pathogen. In addition, S. pyogenes does not express PC on its
surface, and to which bacterial surface structure SAP binds
may inﬂuence its functional role and interactions with
complement factors. For example, de Haas et al. have
reported that in direct contrast to the results presented in
this manuscript, binding of SAP to the LPS expressed by some
E. coli strains inhibits classical pathway–mediated comple-
ment activity, perhaps by preventing direct binding of C1q to
LPS [29]. Further research is required to identify whether
SAP mediates complement-dependent immunity to other
important pathogens, and to determine why SAP has
contrasting effects on susceptibility to closely related
pathogens such as S. pneumoniae and S. pyogenes.
In summary, we have demonstrated that SAP aids comple-
ment activity against S. pneumoniae and is an important
component of the innate immune response to this pathogen.
To our knowledge, this is the ﬁrst report demonstrating a
positive role for SAP in complement-mediated immunity to a
microbial pathogen. The data make a signiﬁcant contribution
to our understanding of the biological role of SAP and to our
knowledge of the complex mechanisms leading to activation
of complement by S. pneumoniae.
Materials and Methods
Bacteria. S. pneumoniae strains belonging to capsular STs 2 (D39), 4
(JSB4, previously M313), and 23F (JSB23F, previously Io11697) were
used for the majority of the studies [53]. The E. coli strain O111:B4
and the S. pyogenes strain H372 were used for SAP binding assays
[30,52]. S. pneumoniae and S. pyogenes strains were cultured in Todd-
Hewitt broth supplemented with 0.5% yeast extract (Oxoid, http://
www.oxoid.com/) while E. coli O111:B4 was cultured in LB broth
(Oxoid). All strains were grown to an optical density (OD580) of 0.4
(corresponding to about 10
8 cfu/ml) and stored at  70 8C in 10%
glycerol as single-use aliquots.
ELISA for SAP binding to S. pneumoniae. SAP binding to S.
pneumoniae was analysed by whole-cell ELISA as previously described
[54]. Brieﬂy, bacterial cultures from late log phase were resuspended
in PBS to an OD550 of 1.0, 200 ll of this suspension added to each well
of 96-well plates (Nunc MaxiSorp, http://www.nuncbrand.com/), air
dried at room temperature, and blocked with 200 ll of PBS-0.5 %
BSA-NaN3 for 1 h before 50 ll of different concentrations of hSAP
(Calbiochem, http://www.emdbiosciences.com/html/CBC/home.html)
were added to each well. After incubation overnight at 4 8C, the
plates were incubated with 50 ll of rabbit anti-human SAP
(Calbiochem) diluted 1/2000 for 5 h at 4 8C, incubated overnight
with 50 ll of goat anti-rabbit AP (Sigma, http://www.sigmaaldrich.
com/) diluted 1/1000, and developed using FAST p-nitrophenyl
phosphate (Sigma) for 30 min before determining the OD405 using
a microtiter plate reader (Multiskam ACC/340; Titertek, http://www.
titertek.com/).
C3b, C1q, CRP, and SAP Binding to S. pneumoniae. C3b deposition
on S. pneumoniae was measured using a ﬂow cytometry assay as
previously described [34,52]. Brieﬂy, 10
7 cfu of S. pneumoniae were
incubated with 10 ll of serum from wild-type or Apcs
 /  mice and
bacteria coated with C3b identiﬁed using a FITC-goat anti mouse C3
antibody and ﬂow cytometry. CRP, SAP, and C1q binding assays were
performed by a similar assay using either rabbit anti-human SAP or
CRP (Calbiochem, with an appropriate FITC labelled secondary
antibody) or FITC sheep anti-human C1q antibody (Serotec, http://
www.ab-direct.com/), and incubating at 37 8C S. pneumoniae for 1 h
with serum with or without addition of EDTA or PC (Sigma), 10 or 50
lg/ml hSAP (Calbiochem), and/or human C1q protein (Calbiochem).
C3 levels (measured by ELISA) in the serum of Apcs
 /  and wild-type
mice were similar at 332 mg/l SD 101.7 (n ¼ 40) for Apcs
 /  mice, and
357 mg/l SD 123.5 (n ¼ 20) for C57B/6 mice. Serum deﬁcient in both
C1q and SAP was obtained from Apcs
 / .C1qa
 /  mice created by
interbreeding the previously described Apcs
 /  and C1qa
 /  mouse
strains [5,55]. C1q binding assays were also performed in human
serum depleted in C1q (Calbiochem) with or without addition of 50
lg/ml of hSAP protein, using a serum that had been treated similarly
by depletion of a terminal complement pathway component (C9,
Calbiochem) to represent normal serum.
Phagocytosis assays. Phagocytosis of S. pneumoniae in serum from
Apcs
 / , Apcs
 / .C1qa
 / , and wild-type mice was investigated using a
previously described ﬂow cytometry assay and the human tissue
culture cell line HL-60 (promyelocytic leukemia cells; CCL240;
American Type Culture Collection, http://www.atcc.org/) differenti-
ated into granulocytes [53,56]. S. pneumoniae were ﬂuorescently
labelled with 5,6-carboxyﬂuorescein succinimidyl ester (FAM-SE;
Molecular Probes, http://probes.invitrogen.com/) as described and
stored at 70 8C in 10% glycerol as single-use aliquots (7310
8 cfu/ml).
FAM-SE-labelled bacteria (10
6 cfu) were opsonised with 10 llo f
dilutions of serum obtained from wild-type or Apcs
 /  mice in a 96-
well plate for 20 min at 37 8C with horizontal shaking (150 rpm). HL-
60 cells (10
5) were added to each well and incubated for 30 min at 37
8C, ﬁxed with 3% PFA, and analysed using a FACScalibur ﬂow
cytometer (minimum of 6,000 cells per sample) to identify the
proportion of cells associated with ﬂuorescent bacteria as a marker of
phagocytosis [43].
Infection experiments. Wild-type C57BL/6 mice were purchased
from commercial breeders, and Apcs
 /  and C57BL/6.129(D1Mit105–
223) congenic mice were bred in-house by one of the authors (MB)
[5,42]. All mice used were 8–16 wk old, and within each experiment
groups of mice were matched for age and sex. Studies were
performed according to UK Home Ofﬁce and university guidelines
for animal use and care. Mice were inoculated i.n. (under halothane
anesthesia, 1 3 10
6 cfu/mouse) or intravenously (1 3 10
6 cfu/mouse)
with the S. pneumoniae D39 strain appropriately diluted in PBS. For
survival studies, mice were killed when they exhibited signs of severe
disease from which recovery was unlikely [57]. For experiments to test
the number of cfu in different target organs or to perform
immunological analysis, target organs were recovered 4 and 24 h
after inoculation as previously described [34]. Bacterial counts were
calculated by plating serial dilutions of the homogenised organs
suspensions, blood, and BALF onto blood agar and incubated at 37 8C
in 5% CO2.
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levels of inﬂammatory cytokines and chemokines (IL-6, IL-10, MCP-1,
IFN-c,T N F - a, and IL-12p70) in BALF were analysed by ﬂow
cytometry in 50 ll of pooled BALF from wild-type or Apcs
 /  mice
using the Mouse Inﬂammation Cytometric Bead Array kit (Becton
Dickinson, http://www.bdbiosciences.com/) according to manufac-
turer protocols and using the BD CBA software [52]. For the
histological analysis of inﬂammation, in a proportion of infection
experiments the left lung was ﬁxed in 4% neutral buffered formalin,
processed to parafﬁn wax, and stained with haematoxylin and eosin.
Inﬂammation was assessed using a simpliﬁed score based on a
previously described scoring system for inﬂammation during S.
pneumoniae pneumonia [58]. The extent of lung involvement was
estimated by examining lung cross sections at310 magniﬁcation. The
degree of inﬂammation for six ﬁelds was scored at 3200 magniﬁca-
tion as 1 (no visible inﬂammatory change), 2 (minimal swelling of
alveolar walls with slight change in architecture), 3 (increased swelling
with presence of erythrocytes and inﬂammatory cells and an increase
in type II pneumocytes), and 4 (considerable haemorrhage with
inﬂammatory cell inﬂux, widespread alveolar disorganisation with
interstitial swelling and pneumocyte proliferation). A total score for
each mouse was obtained by multiplying the percentage of involved
lung by the mean score for the areas analysed, and data presented as
medians with IQRs.
Statistical analysis. The complement factor binding and opsono-
phagocytosis data presented are representative of results obtained
from several independent experiments. The data for mouse infection
experiments are representative of duplicate experiments that gave
similar results. The results of C3b deposition, C1q, CRP and SAP
binding experiments, cytokine levels, and phagocytosis assays were
analysed using 2-tailed t tests. Bacterial cfu recovered from target
organs and histology scoring were analysed using the Mann–Whitney
U test for non-parametric data. Differences in survival curves
between mouse strains were compared using the log rank method.
All error bars given on the ﬁgures represent standard deviations.
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